comparemela.com

Latest Breaking News On - Zaiqi wang - Page 1 : comparemela.com

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline

/PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicated on developing innovative therapies to overcome treatment resistance for.

San diegoUnited statesZaiqi wangPrnewswire inxmed co ltdInxmed co ltdAnnual worldChief executive officerInxmed coHealth care amp hospitalsMedical pharmaceuticalsTrade show newsClinical trials amp medical discoveries

GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development

/PRNewswire/ On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology.

Gang qinUnited statesZaiqi wangDrug administrationChina national medical products administrationFocal adhesion kinaseFast track designationBreakthrough therapy designationChina national medical productsGenequantum healthcare

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer

NANJING, China, May 29, 2022 /PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies.

United statesZaiqi wangChina national medical products administrationPrnewswire inxmed co ltdAmerican society of clinical oncologyBoehringer ingelheimDrug administrationAmerican societyClinical oncology

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies t.

United statesZaiqi wangInxmed nanjing translational medicine centerChina national medical products administrationPrnewswire inxmed co ltdDrug administrationMed nanjing translational medicine centerAnnual meetingAmerican societyClinical oncologyChief executive officerHyfinity investmentsBoehringer ingelheim about hyfinity

InxMed raises funding to advance new cancer therapies

InxMed has raised $15m in Series B+ financing funded by Hyfinity Investments to advance new therapies for the treatment of drug-resistant cancers.

Zaiqi wangChina national medical products administrationDrug administration

vimarsana © 2020. All Rights Reserved.